Regeneron (RGO) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Regeneron DE:RGO is currently developing the following drugs: Cemiplimab, Fianlimab, Vidutolimod, Regn2810, Regn3767, Libtayo, Olatorepatide, Regn-2Cat, Freneslerbart, Mevonlerbart, Regn1908, Regn1909, Dupilumab, Dupilumab Coformulated With Berahyaluronidase Alfa, Sar231893, Dupixent, Regn7508, Apixaban, Tocilizumab, Linvoseltamab, Regn5458, Actemra, Regn15505, Regn15505+Cemiplimab, Regn15505+Regn4336, Regn2810, Libtayo, Regn20934, Garetosmab, Regn2477, Bpx-601, Regn20423, Tirzepatide, Aln-Pnp, Itepekimab, Regn3500, Alirocumab, Praluent, Linvoseltamab, Regn17372+Linvoseltamab, Regn5458, Regn9933, Regn7508, Regn7508, Dexamethasone, Bortezomib, Lenalidomide, Daratumumab, Linvoseltamab, Regn5458, Linvoseltamab, Daratumumab, Regn5458, Darzalex Faspro, Regn9933, Regn7508, Rivaroxaban, Regn13335, Regn5713, Regn5715, Sarilumab, Evinacumab, Aln-Ang3, Mibavademab, Regn4461, Pozelimab, Dexamethasone, Daratumumab, Carfilzomib, Pomalidomide, Bortezomib, Linvoseltamab, Mibavademab, Regn7041, Aln-Snca, Aln-5288, Regn7508, Acetylsalicylic Acid, Aln-Cfb, Dupilumab, Apixaban, Regn7508, Regn9933, Ubamatamab, Sarilumab, Regn7075. These drug candidates are in various stages of clinical development as the company works toward FDA approval.